Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

NCT06492421 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Surgery
Non-small Cell Lung Cancer

Interventions

DRUG: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab

Sponsor

Second Affiliated Hospital of Guangzhou Medical University